Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00491478
Other study ID # R01HD030615
Secondary ID
Status Recruiting
Phase Phase 3
First received June 22, 2007
Last updated June 22, 2007
Start date September 1992

Study information

Verified date May 2003
Source Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Contact Mark Lewis, PhD
Phone 352-392-3471
Email mlewis@psych.med.ufl.edu
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

Repetitive behavior disorders are prevalent among people with severe mental retardation. These disorders can interfere significantly with an individual’s daily functions. This trial is part of a long-term project that has studied the biologic basis of and possible treatments for repetitive behavior disorders. The trial will evaluate the effectiveness of two medications, a selective serotonin reuptake inhibitor (SSRI) and an atypical antipsychotic, in treating repetitive behavior disorders in people with mental retardation.


Description:

Abnormal repetitive behaviors (odd or inappropriate movements, self-injury, and compulsions) are among the aberrant behaviors exhibited by individuals with mental retardation. However, little is known about their pathobiology and treatments are largely unconfirmed by controlled trials. For example, few controlled studies have examined the efficacy of pharmacological treatment of abnormal repetitive behavior in individuals with mental retardation.

This trial is part of a larger project designed to elucidate the neurobiological bases of repetitive behavior disorders and to develop rational, safe, and effective pharmacological treatments. Thus far, the project has established a pathophysiological basis for stereotyped behavior disorder, demonstrated the role of central dopamine deficiency in stereotyped behavior disorder, and provided evidence of the efficacy of both 5-HT uptake inhibitors and atypical antipsychotics in treating stereotyped behaviors.

There is currently little information to guide the clinician in deciding which drug class may be more effective for which abnormal repetitive behaviors and for which individuals. Moreover, little work has attempted to identify variables that may predict differential treatment response. This trial will assess the relative efficacy of an SSRI and an atypical antipsychotic across multiple categories of abnormal repetitive behaviors.


Recruitment information / eligibility

Status Recruiting
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria

- Mental retardation

- Medically stable resident of either Western Carolina Center, Morganton, NC or Tacachale Community, Gainesville, FL

- Free of sensory deficits

- Ambulatory

- High rate of stereotyped behavior that may co-occur with self-injurious or compulsive behaviors

Exclusion Criteria

- Poor general health

- Cardiac, hepatic, or renal abnormalities

- Seizure within 4 months prior to study entry (patients on seizure medication who have not had a seizure within 4 months prior to study entry may participate)

- Tardive dyskinesia

- Akathisia

- Neuroleptic use within 6 months of study entry

- History of sensitivity to ergot alkaloids

- Hypertension

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
sertraline


Locations

Country Name City State
United States Department of Psychiatry Gainesville Florida
United States Western Carolina Center Morganton North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Bodfish JW, Crawford TW, Powell SB, Parker DE, Golden RN, Lewis MH. Compulsions in adults with mental retardation: prevalence, phenomenology, and comorbidity with stereotypy and self-injury. Am J Ment Retard. 1995 Sep;100(2):183-92. — View Citation

Bodfish JW, Parker DE, Lewis MH, Sprague RL, Newell KM. Stereotypy and motor control: differences in the postural stability dynamics of persons with stereotyped and dyskinetic movement disorders. Am J Ment Retard. 2001 Mar;106(2):123-34. — View Citation

Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000 Jun;30(3):237-43. — View Citation

Lewis MH, Bodfish JW, Powell SB, Wiest K, Darling M, Golden RN. Plasma HVA in adults with mental retardation and stereotyped behavior: biochemical evidence for a dopamine deficiency model. Am J Ment Retard. 1996 Jan;100(4):413-8. — View Citation

See also
  Status Clinical Trial Phase
Completed NCT02791321 - Fragility Assessment in Adults With ADHD and Mental Retardation N/A
Recruiting NCT01908400 - Safety and Efficacy of BMMNCin Patients With Mental Retardation Phase 1/Phase 2
Withdrawn NCT02245724 - Stem Cell Therapy in Mental Retardation Phase 1
Completed NCT00156221 - MR Scanning of Very Young Children With Severe Developmental Disorders N/A
Terminated NCT02797418 - "Cognitus & Moi": a New Cognitive Remediation Tool N/A
Completed NCT00758108 - Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions
Completed NCT01430845 - Predicting Developmental Disability Type and Mental Retardation Level in Children With General Developmental Delay
Not yet recruiting NCT02214745 - Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community N/A
Active, not recruiting NCT00552526 - Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy Phase 4
Completed NCT02943304 - Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
Completed NCT00491894 - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Phase 3
Completed NCT01291238 - School Intervention With Daily Physical Activity and Healthy Food for Students With an Intellectual Disability. N/A
Completed NCT01456910 - Resistance Training Program, Labor Inclusion, Intellectual Disability N/A
Completed NCT00065273 - Atypical Neuroleptic Drugs in People With Mental Retardation/Developmental Delay Phase 3
Active, not recruiting NCT00065936 - Self-Injury: Diagnosis and Treatment Phase 3
Completed NCT00506259 - Treatment Strategies for Children With Smith-Magenis Syndrome Phase 1
Not yet recruiting NCT05442229 - A Cross-sectional Study to Evaluate Speech and Language Development in Chinese Children Aged 2-6 Years
Active, not recruiting NCT06370793 - Ningbo Severe Mental Disorders Cohort
Completed NCT01517048 - Brain-Derived Neurotrophic Factor in Obesity and Brain Function
Completed NCT03847753 - Exploring the Comorbidity Between Mental Disorders and General Medical Conditions